Disease modifying therapies III: Novel targets

Area of Science:

• Neuroscience
• Biochemistry
• Gastroenterology

Background:

• Current Parkinson's disease (PD) treatments primarily offer symptomatic relief, not disease modification.
• Understanding PD pathogenesis reveals novel targets for halting or reversing neurodegeneration.
• Patient stratification and biomarker development are crucial for effective clinical trials.

Purpose of the Study:

• To review emerging PD targets and strategies for disease modification.
• To explore the role of neuroinflammation, lysosomal dysfunction, and insulin resistance in PD progression.
• To investigate the potential of targeting the gastrointestinal tract for PD treatment.

Main Methods:

• Review of preclinical studies and current clinical trial status.
• Analysis of novel PD-related mechanisms including neuroinflammation and lysosomal dysfunction.
• Exploration of peripheral interfaces, specifically the gastrointestinal tract and its microbiome.

Main Results:

• Emerging targets like neuroinflammation, lysosomal dysfunction, and insulin resistance show promise for PD modification.
• The gastrointestinal tract and its ecosystem present a viable peripheral interface for therapeutic intervention.
• Biomarkers are essential for patient stratification and measuring target engagement in clinical trials.

Conclusions:

• Targeting novel pathways and peripheral interfaces offers potential for modifying Parkinson's disease progression.
• Integrating biomarkers into clinical trials will enhance patient selection and outcome assessment.
• Further research into these mechanisms and targets is warranted to develop effective disease-modifying therapies for PD.